CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...
Phase 2
Plainfield, Indiana, United States and 35 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
Plainfield, Indiana, United States and 73 other locations
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...
Phase 2
Indianapolis, Indiana, United States and 32 other locations
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...
Phase 3
Indianapolis, Indiana, United States of America and 36 other locations
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...
Phase 3
Indianapolis, Indiana, United States of America and 41 other locations
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
Phase 2
Plainfield, Indiana, United States and 4 other locations
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...
Phase 2
Plainfield, Indiana, United States and 39 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Indianapolis, Indiana, United States and 179 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Plainfield, Indiana, United States and 83 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Indianapolis, Indiana, United States of America and 234 other locations
Clinical trials
Research sites
Resources
Legal